Journal article
Studies on enmetazobactam clarify mechanisms of widely used β-lactamase inhibitors
- Abstract:
- β-Lactams are the most important class of antibacterials, but their use is increasingly compromised by resistance, most importantly via serine β-lactamase (SBL)-catalyzed hydrolysis. The scope of β-lactam antibacterial activity can be substantially extended by coadministration with a penicillin-derived SBL inhibitor (SBLi), i.e., the penam sulfones tazobactam and sulbactam, which are mechanism-based inhibitors working by acylation of the nucleophilic serine. The new SBLi enmetazobactam, an N-methylated tazobactam derivative, has recently completed clinical trials. Biophysical studies on the mechanism of SBL inhibition by enmetazobactam reveal that it inhibits representatives of all SBL classes without undergoing substantial scaffold fragmentation, a finding that contrasts with previous reports on SBL inhibition by tazobactam and sulbactam. We therefore reinvestigated the mechanisms of tazobactam and sulbactam using mass spectrometry under denaturing and nondenaturing conditions, X-ray crystallography, and NMR spectroscopy. The results imply that the reported extensive fragmentation of penam sulfone–derived acyl–enzyme complexes does not substantially contribute to SBL inhibition. In addition to observation of previously identified inhibitor-induced SBL modifications, the results reveal that prolonged reaction of penam sulfones with SBLs can induce dehydration of the nucleophilic serine to give a dehydroalanine residue that undergoes reaction to give a previously unobserved lysinoalanine cross-link. The results clarify the mechanisms of action of widely clinically used SBLi, reveal limitations on the interpretation of mass spectrometry studies concerning mechanisms of SBLi, and will inform the development of new SBLi working by reaction to form hydrolytically stable acyl–enzyme complexes.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.0MB, Terms of use)
-
- Publisher copy:
- 10.1073/pnas.2117310119
Authors
Innovation Medicines Initiative
More from this funder
- Publisher:
- National Academy of Sciences
- Journal:
- Proceedings of the National Academy of Sciences More from this journal
- Volume:
- 119
- Issue:
- 18
- Article number:
- e2117310119
- Publication date:
- 2022-04-29
- Acceptance date:
- 2002-03-14
- DOI:
- EISSN:
-
1091-6490
- ISSN:
-
0027-8424
- Pmid:
-
35486701
- Language:
-
English
- Keywords:
- Pubs id:
-
1255290
- Local pid:
-
pubs:1255290
- Deposit date:
-
2022-11-16
- ARK identifier:
Terms of use
- Copyright holder:
- Lang et al.
- Copyright date:
- 2022
- Rights statement:
- Copyright © 2022 the Author(s). Published by PNAS. This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record